X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Scrutinises 2 Cancer Permits Sans Voluntary Withdrawals

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    NICE Advises Imcivree By Rhythm To Treat Obesity And Hunger

    NICE Advises Imcivree By Rhythm To Treat Obesity And Hunger

    Researchers Push For Antibiotic Nod In Brazil, India, And SA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Scrutinises 2 Cancer Permits Sans Voluntary Withdrawals

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    BA.5 Causes Greater COVID-19 Reinfections, But Not Often

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    Azurity Gets FDA Nod On Liquid Epilepsy Drug After Rejection

    NICE Advises Imcivree By Rhythm To Treat Obesity And Hunger

    NICE Advises Imcivree By Rhythm To Treat Obesity And Hunger

    Researchers Push For Antibiotic Nod In Brazil, India, And SA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

Content Team by Content Team
30th July 2022
in Drug Development, News
Paxlovid Allowed By FDA To Sell At Certified Pharmacies

Pfizer is prepared and equipped to continue its pandemic sales supremacy, the company’s chief executive said on a July 28 investor call, even if federal contracts for COVID-19 antivirals and vaccines dry up.

During the company’s second-quarter earnings call, CEO Albert Bourla stated, in terms of their commercial leadership, they feel Pfizer’s skills are even more equipped for functioning in free markets than they are for the federal contract market. Bourla predicts that Pfizer will be much more aggressive with its mRNA shot Comirnaty and its oral antiviral Paxlovid once the pandemic market transforms into an endemic one.

Bourla made his comments as Pfizer reported overall second-quarter sales of $27.7 billion, up 53% from the same period last year. Paxlovid contributed $8.1 billion and Comirnaty $8.8 billion of the total, respectively. Aside from COVID, Pfizer saw an increase in sales from Vyndamax, which increased by 16% to $552 million, and its collection of Prevnar vaccinations for pneumococcal illness, which brought in $1.4 billion globally.

Pfizer’s CEO reiterated past cautions that the pandemic might become a reality, something which wouldn’t inevitably have a negative impact on the company’s top line.

Like everybody else, they would wish that this global health catastrophe would end quickly after two and a half years, Bourla remarked. The CEO noted that while hope is vital, science is not hope and that COVID-19 certainly will remain a significant worldwide health issue for years to come. Pfizer remained committed to its COVID-19 product revenue prediction despite some efficacy and demand concerns. It confirmed estimates that Paxlovid and Comirnaty would produce $22 billion and $32 billion in revenue, respectively, for the entire year.

Due to difficult eligibility conditions, limited testing, the possibility of drug interactions, and the public’s impression that omicron infections aren’t as serious, Paxlovid demand earlier this year fell short of Pfizer’s expectations.

However, Bourla claims that Pfizer is currently quite satisfied with the antiviral’s course in the United States, where as of July 15, there are currently more than 41,000 locations with Paxlovid supplies. According to Bourla, that number is up more than 7,000 since early May.

Bourla also hailed the FDA’s recent decision to permit the drug to be given at pharmacies, stating that the business has already seen Paxlovid use rise five-fold in the United States during the first quarter. The CEO went on to say that Pfizer is engaging important government authorities to explore their access strategy on a state-by-state basis.

In addition, Bourla said, the company keeps educating states, medical professionals, and pharmacists about Paxlovid’s potential in all eligible high-risk patients, not just immunocompromised and unvaccinated individuals. Paxlovid may not always be in the spotlight, though. A second wave of booster vaccines and forecasts of fewer numbers requiring hospitalisation are expected to cause Paxlovid revenues to decline starting in 2023 after reaching a sales peak in 2022, according to a new prediction by GlobalData.

Additionally, poor results have forced Pfizer to halt enrollment in a Paxlovid clinical trial assessing the antiviral in patients at standard risk, stifling demand in that larger patient population. Pfizer maintained its full-year sales target for 2022, which ranges from $98 billion to $102 billion.

Previous Post

GSK To Aid 12 European Countries Prepare For Future Pandemic

Next Post

NHS Lays Long COVID Action Plan For Many With Chronic Signs

Related Posts

NHS Lays Long COVID Action Plan For Many With Chronic Signs
Facilities & Operation

NHS Lays Long COVID Action Plan For Many With Chronic Signs

30th July 2022
GSK Unveils Its Transformation Through New Branding And Logo
News

GSK To Aid 12 European Countries Prepare For Future Pandemic

29th July 2022
COVID-19 Grant Turned To Telehealth Service At MaineHealth
Health & Nutrition

COVID-19 Grant Turned To Telehealth Service At MaineHealth

27th July 2022
Indian Government Launches Three MSMEs Pharma Programmes
News

Indian Government Launches Three MSMEs Pharma Programmes

26th July 2022
Overall Coronavirus Monoclonal COVID-19 Variant Treatment
News

Overall Coronavirus Monoclonal COVID-19 Variant Treatment

26th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
FDA Approvals

FDA Scrutinises 2 Cancer Permits Sans Voluntary Withdrawals

25th July 2022
Next Post
NHS Lays Long COVID Action Plan For Many With Chronic Signs

NHS Lays Long COVID Action Plan For Many With Chronic Signs

Latest News

NHS Lays Long COVID Action Plan For Many With Chronic Signs
Facilities & Operation

NHS Lays Long COVID Action Plan For Many With Chronic Signs

30th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Drug Development

Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

30th July 2022
GSK Unveils Its Transformation Through New Branding And Logo
News

GSK To Aid 12 European Countries Prepare For Future Pandemic

29th July 2022
COVID-19 Grant Turned To Telehealth Service At MaineHealth
Health & Nutrition

COVID-19 Grant Turned To Telehealth Service At MaineHealth

27th July 2022
Indian Government Launches Three MSMEs Pharma Programmes
News

Indian Government Launches Three MSMEs Pharma Programmes

26th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In